BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9820633)

  • 21. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study.
    Köppler H; Pflüger KH; Eschenbach I; Pfab R; Lennert K; Wellens W; Schmidt M; Gassel WD; Kolb T; Hässler R
    Br J Cancer; 1989 Jul; 60(1):79-82. PubMed ID: 2679846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group.
    Cameron DA; White JM; Proctor SJ; Prescott RJ; Leonard RC; Angus B; Cook MK; Dawes PJ; Dawson AA; Evans RG; Galloway MJ; Harris AL; Heppleston A; Horne CH; Krajewski AS; Lennard AL; Lessells AM; Lucraft HH; MacGillivray JB; Mackie MJ; Parker AC; Roberts JT; Taylor PR; Thompson WD
    Eur J Cancer; 1997 Jul; 33(8):1195-201. PubMed ID: 9301442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.
    Singer JM; Mijovic A; Pettingale KW; Nethersell A; Dobbs HJ; Samaratunga IR; Lakhani A; Mufti GJ
    Clin Oncol (R Coll Radiol); 1995; 7(6):366-70. PubMed ID: 8590697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
    Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
    Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma.
    Bessell EM; Burton A; Haynes AP; Glaholm J; Child JA; Cullen MH; Davies JM; Smith GM; Ellis IO; Jack A; Jones EL;
    Ann Oncol; 2003 Feb; 14(2):258-67. PubMed ID: 12562653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.
    Perren TJ; Selby PJ; Milan S; Meldrum M; McElwain TJ
    Br J Cancer; 1990 Jun; 61(6):919-23. PubMed ID: 1695523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensive treatment of stage III-IV aggressive malignant lymphomas (protocol TPL-84).
    Colombat P; Guilhot F; Bordesoule D; Renou P; Benz-Lemoine E; Fouillard L; Drouet M; Tanzer J; Lamagnere JP
    Haematologica; 1991; 76(6):479-84. PubMed ID: 1726492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Third generation chemotherapy with P-VABEC for aggressive non-Hodgkin's lymphomas of the elderly.
    Caracciolo F; Petrini M; Capochiani E; Papineschi F; Grassi B
    Leuk Lymphoma; 1993 Sep; 11(1-2):115-8. PubMed ID: 8220144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Pfreundschuh M; Zwick C; Zeynalova S; Dührsen U; Pflüger KH; Vrieling T; Mesters R; Mergenthaler HG; Einsele H; Bentz M; Lengfelder E; Trümper L; Rübe C; Schmitz N; Loeffler M;
    Ann Oncol; 2008 Mar; 19(3):545-52. PubMed ID: 18065407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
    Dreiher J; Shpilberg O; Raanani P; Chetrit A; Ben-Bassat I
    Leuk Res; 1998 Nov; 22(11):997-1002. PubMed ID: 9783801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.
    Bezwoda W; Rastogi RB; Erazo Valla A; Diaz-Maqueo JC; Pavlovsky S; Morioka H; Resegotti L; Rueckle H; Somoza N; Moreno-Nogueira JA
    Eur J Cancer; 1995 Jun; 31A(6):903-11. PubMed ID: 7646919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
    Sawada M; Tsurumi H; Yamada T; Hara T; Fukuno K; Goto H; Shimizu M; Kasahara S; Yoshikawa T; Kanemura N; Oyama M; Takami T; Moriwaki H
    Eur J Haematol; 2002 Jun; 68(6):354-61. PubMed ID: 12225393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
    Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
    Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of CHEP and CHOP chemotherapy in the management of non-Hodgkin's lymphoma].
    Chen J; Wang Z
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):209-11. PubMed ID: 10920899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology).
    Montserrat E; García-Conde J; Viñolas N; López-Guillermo A; Hernández-Nieto L; Zubizarreta A; Maldonado J; Alcalá A; Faura MV; Llorente A; Bladé J; Fontanillas M; Estapé J
    Eur J Haematol; 1996 Nov; 57(5):377-83. PubMed ID: 9003479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
    Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F
    Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma.
    Niitsu N; Okamoto M; Kohori M; Aoki S; Miura I; Hirano M
    Hematol Oncol; 2006 Dec; 24(4):220-6. PubMed ID: 16958147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.